Clin2
NCT07556653Possibly a fitRecruiting

New cell therapy for advanced solid tumors

Advanced Solid Tumors

Part of Cancer clinical trials.

This early-stage trial tests a new allogeneic cell therapy (WTX-212C) designed to fight advanced solid cancers. Researchers want to see if this treatment is safe and how well it works in patients whose cancer has spread.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
24 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Age 18–75 years
  • Advanced solid cancer confirmed by biopsy or tissue sample
  • At least one tumor visible on imaging that can be measured
  • Good overall health and ability to do light activities (ECOG score 0–1)
  • Normal liver, kidney, and blood counts
  • Expected to live at least 12 weeks

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07260058Not yet recruiting· Phase 1/Phase 2
Immune cell therapy for advanced solid tumors

This trial tests a new immune cell therapy for people with advanced solid tumors of the lung, liver, colon, rectum, or breast. It aims to see if the treatment is safe and can help shrink or control the cancer.

NCT07207681Not yet recruiting· Phase 1
Personalized T-cell therapy for advanced solid tumors

This trial tests a personalized treatment made from your own immune cells (T-cells) that are modified to attack your tumor. It is for people with advanced solid tumors that have not responded to standard treatments.

Changchun, Jilin
NCT07275853Not yet recruiting· Phase 1
Personalized immune cell therapy for advanced solid tumors

This trial tests a personalized cell therapy that uses your own immune cells (T-cells) specially modified to target your tumor. It is for people with advanced solid tumors who have run out of standard treatment options.

Beijing
NCT07589530Recruiting· Phase 1/Phase 2
CAR NK Cell Therapy for Advanced Solid Tumors

This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.

Shenzhen, Guangdong
NCT06026605Recruiting· Early Phase 1
Study of WTX212A for advanced solid tumors

This trial tests a new drug called WTX212A for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to find the best dose and see if the drug is safe and effective.

Hangzhou, Zhejiang
NCT05831033Recruiting· Early Phase 1
Your own immune T-cells to treat advanced solid tumors

This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.

Shanghai, Shanghai Municipality

Hear when a new Advanced Solid Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.